Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Oncology Information Systems Market Size, Share & Trends Analysis Report by Products & Services (Software, Professional Services),...
-
UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancer
-
STUDIO CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members and longtime...
-
ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the...
-
STUDIO CITY, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members and longtime...
-
Der Gewebeschnitt-Scanner ZEISS Axioscan 7 spatial biology erlaubt skalierbare Workflow-Automatisierung- Umfassendes Lösungsportfolio für die Herausforderungen in der klinischen Forschung – von...
-
Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation - Comprehensive solution portfolio – from multiplex immunofluorescence (mIF) staining reagents to spatial image...
-
BPGbio presents new research on the power of mitochondrial medicine and protein homeostasis technologies to address aggressive cancers at AACR.
-
Alberta Cancer Foundation (ACF) is joining the Creative Destruction Lab Cancer program to accelerate commercialization of tech to transform cancer care.
-
CAMBRIDGE, United Kingdom and NEW YORK, April 15, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...